Given the fact that our result shows ccRCC patients with mTOR mutation live longer than others, we predict hyper-activating mutated mTOR in ccRCC somehow inhibits tumorigenesis. The gene discussed is MTOR; the disease is nonpapillary renal cell carcinoma.